Business
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway – CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Ra
About this update from Solid Biosciences Inc.
[{"type":"image","alt":"Solid Biosciences Inc.","displaySize":"","headline":null,"caption":"Solid Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sCFNOglu1.GlZmhoavpsMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef","width":300,"height":169}},"lazy":false},{"type":"text","content":"– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations –","length":88,"tagName":"p"},{"type":"text","content":"– SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia –","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"– FALCON Phase 1b clinical trial participant screening underway –","length":65,"tagName":"p"},{"type":"text","content":"CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for SGT-212, the Company’s investigational gene therapy for Friedreich’s ataxia (FA). SGT-212 will deliver the full-length frataxin gene via dual routes of administration, utilizing both direct intradentate nucleus (IDN) and intravenous (IV) infusions, and was designed to promote restoration of therapeutic levels of the frataxin protein to address neurologic, cardiac and systemic clinical manifestations of FA.","length":753,"tagName":"p"},{"type":"text","content":"Rare Pediatric Disease designation is granted by the FDA for serious and life-threatening diseases that primarily affect individuals under 18 years of age. The designation provides the Company with the potential to receive a pediatric priority review voucher (PRV), which can expedite the review for future Biologic License Applications. The PRV may be redeemed to receive priority review for another marketing application or may be sold or transferred.","length":453,"tagName":"p"},{"type":"text","content":"Jessie Hanrahan, Ph.D., Chief Regulatory & Preclinical Operations Officer of Solid Bioscie...